Solana (HSDT) to Release Earnings on Thursday

Key Points

• Helius Medical Technologies (NASDAQ: HSDT) will report its Q1 2026 earnings after the market close on Thursday, May 7, with analysts projecting EPS of ($0.56) and revenue of $2.80 million; a conference call is scheduled for May 19 at 4:00 PM ET.
• Last quarter the company reported an unusually high $4.25 EPS and $5.23M revenue but showed a severe negative net margin (679.54%) and negative ROE; the stock is trading near multi‑month lows (opened $1.98) and analyst ratings are mixed with a consensus target of $3.50.

Solana (NASDAQ:HSDT - Get Free Report) is expected to release its Q1 2026 results after the market closes on Thursday, May 7th. Analysts expect Solana to post earnings of ($0.56) per share and revenue of $2.80 million for the quarter. Interested persons can find conference call details on the company's upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, May 19, 2026 at 4:00 PM ET.

Solana (NASDAQ:HSDT - Get Free Report) last posted its quarterly earnings results on Tuesday, March 31st. The company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of ($26.50) by $30.75. Solana had a negative net margin of 679.54% and a negative return on equity of 104.96%. The firm had revenue of $5.23 million during the quarter, compared to analyst estimates of $0.14 million. On average, analysts expect Solana to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Solana Stock Down 4.8%

NASDAQ:HSDT opened at $1.98 on Thursday. Solana has a 12-month low of $1.59 and a 12-month high of $265.50. The firm has a market capitalization of $108.68 million, a PE ratio of 0.00 and a beta of 0.90. The firm has a 50-day moving average price of $2.03 and a 200 day moving average price of $3.45.

Analysts Set New Price Targets

Several research analysts recently issued reports on HSDT shares. Weiss Ratings reissued a "sell (e+)" rating on shares of Solana in a research report on Tuesday, April 21st. B. Riley Financial started coverage on shares of Solana in a research report on Thursday, April 23rd. They issued a "buy" rating and a $3.00 price target for the company. Zacks Research raised shares of Solana to a "hold" rating in a research report on Monday. Finally, Maxim Group started coverage on shares of Solana in a research report on Monday, April 6th. They issued a "buy" rating and a $4.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $3.50.

Institutional Trading of Solana

Several hedge funds have recently modified their holdings of the company. Geode Capital Management LLC bought a new stake in shares of Solana during the fourth quarter worth $1,006,000. LPL Financial LLC grew its holdings in shares of Solana by 120.1% during the fourth quarter. LPL Financial LLC now owns 382,255 shares of the company's stock worth $1,105,000 after purchasing an additional 208,558 shares during the last quarter. State Street Corp bought a new stake in shares of Solana during the fourth quarter worth $464,000. Cetera Investment Advisers bought a new stake in shares of Solana during the fourth quarter worth $347,000. Finally, Marshall Wace LLP bought a new stake in shares of Solana during the fourth quarter worth $195,000. Institutional investors and hedge funds own 18.63% of the company's stock.

About Solana

Helius Medical Technologies, Inc NASDAQ: HSDT is a medical technology company focused on developing and commercializing non‐invasive neuromodulation platforms designed to enhance neurorehabilitation. Its flagship product, the Portable Neuromodulation Stimulator (PoNS®), delivers mild electrical pulses to the tongue to stimulate neural pathways in conjunction with targeted physical therapy. The device is intended to improve neuroplasticity and support recovery in patients with neurological conditions.

The PoNS system is cleared for use in the United States, Canada and the European Union and is prescribed through specialized rehabilitation clinics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.